Clinical trial
A Phase 3, Open-Label, Baseline-controlled, Multi-center, Sequential Dose-Titration Study to Assess the Pharmacokinetics, Long-Term Efficacy and Safety of Solifenacin Succinate Suspension in Children From 6 Months to Less Than 5 Years of Age With Neurogenic Detrusor Overactivity
NCT01981954 is registered in ClinicalTrials.gov with Astellas Pharma Europe B.V. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Open-Label, Baseline-controlled, Multi-center, Sequential Dose-Titration Study to Assess the Pharmacokinetics, Long-Term Efficacy and Safety of Solifenacin Succinate Suspension in Children From 6 Months to Less Than 5 Years of Age With Neurogenic Detrusor Overactivity
- Lead sponsor
- Astellas Pharma Europe B.V.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- September 25, 2013
- Completion date
- December 18, 2015
- Enrollment
- 23 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.
neurogenic detrusor overactivity, pediatric